As an example, a recent phase-IIa study demonstrated that inaxaplin, a small-molecule compound that inhibits APOL1 function, reduced proteinuria in participants with two APOL1 variants and focal segmental glomerulosclerosis [76]. The gene discussed is APOL1; the disease is focal segmental glomerulosclerosis.